NasdaqGS - Nasdaq Real Time Price USD
Verve Therapeutics, Inc. (VERV)
At close: October 21 at 4:00 PM EDT
After hours: October 21 at 4:20 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
20,648.00
11,758.00
1,941.00
--
--
--
Operating Expense
242,613.00
234,882.00
167,628.00
87,067.00
40,627.00
--
Operating Income
-221,965.00
-223,124.00
-165,687.00
-87,067.00
-40,627.00
--
Net Non Operating Interest Income Expense
27,747.00
23,166.00
6,867.00
142.00
162.00
--
Other Income Expense
1,838.00
165.00
1,486.00
-33,389.00
-5,239.00
--
Pretax Income
-192,380.00
-199,793.00
-157,334.00
-120,314.00
-45,704.00
--
Tax Provision
271.00
275.00
53.00
--
--
--
Net Income Common Stockholders
-192,651.00
-200,068.00
-157,387.00
-120,314.00
-45,704.00
--
Diluted NI Available to Com Stockholders
-192,651.00
-200,068.00
-157,387.00
-120,314.00
-45,704.00
--
Basic EPS
-2.59
-3.12
-2.91
-4.48
-1.57
--
Diluted EPS
-2.59
-3.12
-2.91
-4.48
-1.57
--
Basic Average Shares
75,079.43
64,175.14
54,023.65
26,872.04
29,173.51
--
Diluted Average Shares
75,079.43
64,175.14
54,023.65
26,872.04
29,173.51
--
Total Operating Income as Reported
-221,965.00
-223,124.00
-165,687.00
-87,067.00
-40,627.00
--
Total Expenses
242,613.00
234,882.00
167,628.00
87,067.00
40,627.00
--
Net Income from Continuing & Discontinued Operation
-192,651.00
-200,068.00
-157,387.00
-120,314.00
-45,704.00
--
Normalized Income
-192,651.00
-200,068.00
-157,387.00
-120,314.00
-45,704.00
--
Interest Income
--
--
--
--
162.00
278.00
Net Interest Income
27,747.00
23,166.00
6,867.00
142.00
162.00
--
EBIT
-221,965.00
-223,124.00
-165,687.00
-87,067.00
-40,627.00
--
EBITDA
-215,675.00
-217,669.00
-162,883.00
-85,532.00
-39,299.00
--
Reconciled Depreciation
6,290.00
5,455.00
2,804.00
1,535.00
1,328.00
--
Net Income from Continuing Operation Net Minority Interest
-192,651.00
-200,068.00
-157,387.00
-120,314.00
-45,704.00
--
Normalized EBITDA
-215,675.00
-217,669.00
-162,883.00
-85,532.00
-39,299.00
--
Tax Rate for Calcs
0.00
0.00
0.00
--
--
--
12/31/2019 - 6/17/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BEAM Beam Therapeutics Inc.
23.15
-2.11%
CRBU Caribou Biosciences, Inc.
1.9700
-1.50%
PRME Prime Medicine, Inc.
4.3700
-0.23%
NTLA Intellia Therapeutics, Inc.
20.67
-1.94%
EDIT Editas Medicine, Inc.
3.7600
+11.90%
TNYA Tenaya Therapeutics, Inc.
1.9200
-5.88%
VYGR Voyager Therapeutics, Inc.
7.66
-5.08%
BLUE bluebird bio, Inc.
0.4968
+1.22%
OMGA Omega Therapeutics, Inc.
1.0700
+0.94%
SANA Sana Biotechnology, Inc.
3.9300
-7.09%